Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
about
G protein-coupled receptor kinase 2 promotes flaviviridae entry and replicationFlaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile diseaseRapid molecular assays for the detection of yellow fever virus in low-resource settingsPossible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsA vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuationThe 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T CellsGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineEarly IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responsesVaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in MiceImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesFLAVIdB: A data mining system for knowledge discovery in flaviviruses with direct applications in immunology and vaccinologyT-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifsLive Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern DayAdaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccinationVaccination strategies against Zika virusComparative pathogenesis and systems biology for biodefense virus vaccine development.NIAID workshop on Flavivirus immunity.Methodology for definition of yellow fever priority areas, based on environmental variables and multiple correspondence analysesOccurrence of Autoimmune Diseases Related to the Vaccine against Yellow FeverStability of RNA virus attenuation approachesDissection of antibody specificities induced by yellow fever vaccinationAntibody-mediated neutralization of flaviviruses: a reductionist view.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference?Systems biology of vaccination for seasonal influenza in humans.Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.Implication of haematophagous arthropod salivary proteins in host-vector interactionsYellow Fever 17DD Vaccine Virus Infection Causes Detectable Changes in Chicken Embryos.Limonoids from Melia azedarach Fruits as Inhibitors of Flaviviruses and Mycobacterium tubercolosis.A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse modelVaccinology in the era of high-throughput biology.A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after VaccinationKinetic Study of Yellow Fever 17DD Viral Infection in Gallus gallus domesticus Embryos.The Attenuated Live Yellow Fever Virus 17D Infects the Thymus and Induces Thymic Transcriptional Modifications of Immunomodulatory Genes in C57BL/6 and BALB/C Mice.Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses.Experimental therapies for yellow feverMolecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation.Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.
P2860
Q21562253-01AA9706-A311-407B-8E1A-67BF4C88DDD8Q24273313-1BA84489-697B-4656-B119-CF4FBC09C00EQ24288756-BFC1DE6F-0EFF-4354-AE88-52CBF85AE1E8Q24289014-F0668DA9-14D1-44AD-A5FE-463111167822Q24631128-AED02B46-BBE9-4ABC-A5E9-918963D77BA6Q26700099-A3A4C797-26CE-4C30-A5DC-A1054F2C6502Q26782367-5F8CBD9F-06D3-4A66-B1C9-80E2EF18040DQ27300788-125C6B1C-85C5-4C91-B595-F2BC31E34AEAQ27303766-F52822D3-0508-425C-9533-4F334602ACEBQ27319783-6E4A1EA2-B4CB-4125-ACC4-9C471AE7E0C1Q27469159-73C9BC51-5D52-4D04-B26E-962C33965C24Q28485408-CE272C54-D4E5-497B-A2FC-FACBC1E66976Q28954598-4CD34C2E-5728-4171-B8A8-CEF22F346788Q29274569-FDED60E6-F09D-4A4D-B032-EB49301BFA69Q29571224-8AA150ED-20EA-46F2-BC64-BF2FAF5B0BC8Q33959989-789956D0-CC8A-447D-BF70-2780652060DEQ34142353-73405F1F-D474-4CB2-9BDE-4E85F432470EQ34339754-5BA481DC-7190-4545-A75C-19A17F032497Q34487884-B9FA49C9-A641-4E9E-9421-539A914D3764Q34697416-6EB034C3-9558-4FB8-8C96-F1DEDE8091A0Q34789343-8239DC40-0B41-4F41-899B-B5E6D6C2962EQ34999617-C94173F8-F6B8-447E-838A-7BA7C5E9148BQ35069160-FBF98EA4-CC0F-4591-8CA1-CF75E9D1CC2FQ35082621-9A1CBB77-A3DB-4EE8-8840-26CB49A2790FQ35118722-1CB01626-ED54-4B7D-8993-478B5E80A24BQ35246149-C14557A6-881C-4FD7-A320-331EF20FB059Q35398192-FD4EE5B0-E966-486E-9E0D-F169A5B915C7Q35775796-573DA5F1-F7E7-4968-AD3D-20DA4F2590A8Q35814502-6068AAAF-00FA-4F54-BF62-B7F55C2370E2Q35903209-382B3993-EE2C-4465-B7CD-6DDA229EEE09Q35923851-F08703A8-B85A-4448-85D9-C578EE805314Q35957424-D1BE7095-83EE-4532-8D99-1FC35F5F10FBQ36012072-D83C8993-6A75-49F9-90A0-E9E19C97CC95Q36109321-E35CAF59-AC83-4A82-93D3-CDA9419ABE27Q36577153-8599CFBF-E32F-4B41-9541-17B570730218Q36586306-7A8EF6CA-68CA-40C4-B52B-40E629893468Q36739363-37675E79-1C81-418C-BC1D-59E842BCE727Q37384720-104F7269-F5A7-4531-8F65-DCC41803F117Q37605206-21BD1349-A8A9-43A3-8BC3-E274AD8D7077Q37634164-8A46D5CD-C8C6-4929-9E54-55CE539560AD
P2860
Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Yellow fever vaccine - how doe ...... ous adverse events take place?
@ast
Yellow fever vaccine - how doe ...... ous adverse events take place?
@en
Yellow fever vaccine - how doe ...... ous adverse events take place?
@nl
type
label
Yellow fever vaccine - how doe ...... ous adverse events take place?
@ast
Yellow fever vaccine - how doe ...... ous adverse events take place?
@en
Yellow fever vaccine - how doe ...... ous adverse events take place?
@nl
prefLabel
Yellow fever vaccine - how doe ...... ous adverse events take place?
@ast
Yellow fever vaccine - how doe ...... ous adverse events take place?
@en
Yellow fever vaccine - how doe ...... ous adverse events take place?
@nl
P1476
Yellow fever vaccine - how doe ...... ous adverse events take place?
@en
P2093
Dirk E Teuwen
P304
P356
10.1016/J.COI.2009.05.018
P577
2009-06-10T00:00:00Z